Key result
Volatile anesthetics linked to malignant hyperthermia during antipsychotic polypharmacy, definitively diagnosed by high CICR rate.
Why the study?
Differentiating malignant hyperthermia from neuroleptic malignant syndrome is challenging in patients treated with multiple oral antipsychotics and a history of MARTA-induced CK elevation.
Case Report (n=1)
Malignant hyperthermia can be difficult to differentiate from neuroleptic malignant syndrome in patients on antipsychotic polypharmacy.
Answers are grounded in this paper and cite their sources.
May complicate MH versus NMS differentiation in antipsychotic polypharmacy; single case leaves open prospective validation of CICR testing.
Malignant hyperthermia (MH) occurred during anesthesia with volatile inhalation anesthetics in a patient under treatment with multiple oral antipsychotic drugs and with a history of multi-acting receptor-targeted antipsychotic drug (MARTA)-induced elevation of serum creatine kinase (CK). Since the patient was considered to be at high risk for neuroleptic malignant syndrome (NMS) based on this history, differential diagnosis between MH and NMS was difficult at the time of onset. Later, the patient was found to be predisposed to MH based on abnormal high rate of the Ca 2+ -induced Ca 2+ release (CICR). We concluded that MH was induced by the volatile inhalation anesthetics.
No takes yet. Share an insight, caveat, or question.
Hara et al. (2016) conducted a case report in Malignant hyperthermia (n=1). Volatile inhalation anesthetics (Sevoflurane and Desflurane) was evaluated. A 24-year-old man on antipsychotic polypharmacy developed malignant hyperthermia induced by volatile inhalation anesthetics, which was definitively diagnosed later by an abnormally high CICR rate.
Synapse has enriched 10 related papers. Consider them for comparative context: